Advertisement

Regional chemotherapy

  • Charles F. White
  • Karen Antman
Part of the Cancer Treatment and Research book series (CTAR, volume 30)

Abstract

It is important to the supportive care of many cancer patients to deliver effective antineoplastic therapy selectively to regionally confined tumor. Even in the presence of widespread metastases, regional deposits of cancer often cause specific morbidity. Surgery and radiation therapy, classically considered ‘local cancer therapy’, frequently fail or are contraindicated. Regional chemotherapy in some cases represents the optimal treatment of regionally confined cancer, particularly for palliation.

Keywords

Intraperitoneal Chemotherapy Proc ASCO Regional Chemotherapy Hepatic Artery Infusion Intraarterial Chemotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Frei E, Canellos GP. 1980. Dose: A critical factor in cancer chemotherapy. Am J Med 69:585–594.PubMedCrossRefGoogle Scholar
  2. 2.
    Ensminger WD, Gyves JW. 1984. Regional cancer chemotherapy. Cancer Treat Rep 68:101–115.PubMedGoogle Scholar
  3. 3.
    Collins JM. 1984. Pharmacologic rationale for regional drug delivery. J Clin Oncol 2:498–504.PubMedGoogle Scholar
  4. 4.
    Klopp CT, Alford TC, Bateman et al. 1950. Fractionated intra-arterial cancer chemotherapy with methyl histamine hydrochloride. Preliminary Report. Ann Surg 132:811–832.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Chen HG, Gross JF. 1980. Intraarterial infusion of anticancer drugs: Theoretic aspects of drug delivery and review of responses. Cancer Treat Rep 64:31–40.PubMedGoogle Scholar
  6. 6.
    Eckman WW, Patlak CS, Fenstermacher JD. 1974. A critical evaluation of principles governing the advantages of intraarterial infusions. J Pharmakokinet Biopharm 2:257–285.Google Scholar
  7. 7.
    Wallace, Sidney et al. 1984. Percutaneous transcatheter infusion and infarction in the treatment of human cancer: Part 1. Curr Probl Cancer pp 1–66, Dec.Google Scholar
  8. 8.
    Ensminger WD, Rosowsky A, Raso V et al. 1978. A clinical pharmacologic evaluation of hepatic arterial infusions of 5-Fluoro-2-deoxyuridine and 5-fluorouracil. Cancer Res 38:3784–3792.PubMedGoogle Scholar
  9. 9.
    Freckman HA. 1972. Results in 169 patients with cancer of the head and neck treated by intra-arterial infusion therapy. Am J Surg 124:501–509.PubMedCrossRefGoogle Scholar
  10. 10.
    Baker SR, Wheeler R. 1982. Long term intraarterial chemotherapy infusion of head and neck cancer patients. J Surg Oncol 21:125–131.PubMedCrossRefGoogle Scholar
  11. 11.
    Sutherland CM, Krementz ET. 1982. The role in limb perfusion in the management of malignant melanoma. Post graduate course. Surg Oncol Today pp 119–121.Google Scholar
  12. 12.
    Krementz ET, Carter RD, Sutherland EM et al. 1979. The use of chemotherapy in the management of malignant melanoma. World J Surg 3:289–304.PubMedCrossRefGoogle Scholar
  13. 13.
    Golomb FM. 1976. Perfusion in cancer of the skin. In: Biology, diagnosis, management, Vol. II. Andrade R, Gumport SL, Popkin GL, Rees TD (eds). Philadelphia, W.B. Saunders CO., p 1623.Google Scholar
  14. 14.
    Rosen G, Marcove RC, Huvos AG et al. 1983. Primary osteogenic sarcoma: eight year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol 106 (Suppl):55–67.PubMedGoogle Scholar
  15. 15.
    Eilber FR, Grant T, Morton DL. 1978. Adjuvant therapy for osteosarcoma: Pre-operative treatment. Cancer Treat Rep 62:213–216.PubMedGoogle Scholar
  16. 16.
    Benjamin RS, Chuang VP, Wallace S, Murray J et al. 1982. Pre-operative chemotherapy for osteosarcoma. Proc ASCO 23:174 (C-675).Google Scholar
  17. 17.
    Lathrop JC, Frates RC. 1980. Arterial infusion of nitrogen mustard in the treatment of intractable pelvic pain of malignant origin. Cancer (Feb) 45:432–438.CrossRefGoogle Scholar
  18. 18.
    Wallace S, Chuang VP, Samuels M, Johnson D. 1982. Transcatheter intraarterial infusion of chemotherapy in advanced bladder cancer. Cancer (Feb 15) 40(4):640–645.Google Scholar
  19. 19.
    Logothetis CT, Samuels ML, Wallard S, Chuang V et al. 1982. Management of pelvic complications of malignant urothelial tumors with combined intraarterial and intravenous chemotherapy. Cancer Treat Rep 66:1501–1507.PubMedGoogle Scholar
  20. 20.
    Hafstrom L, Johnson PE, Landberg T et al. 1979. Intraarterial infusion of chemotherapy (5-FU) in patients with inextirpable or locally recurrent rectal cancer. Am J Surg (June) pp 757–762.Google Scholar
  21. 21.
    Sullivan RD, Norcross JW, Watkins E Jr. 1964. Chemotherapy of metastatic liver cancer by prolonged hepatic artery infusion. N Engl J Med 270:321–327.PubMedCrossRefGoogle Scholar
  22. 22.
    Bierman HR, Poyron RL, Kelley KH et al. 1951. Studies on the blood supplies of tumors in man. Vascular patterns of the liver by hepatic arteriography in vivo. J Natl Cancer Inst 12:107–181.PubMedGoogle Scholar
  23. 23.
    Ensminger WD, Rosowsky A, Raso V et al. 1978. A Clinical pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2′-deoxyuridine and 5-fluorouracil. Cancer Res 38:3784–3792.PubMedGoogle Scholar
  24. 24.
    Watkins E, Khazer AM, Nahra KS. 1970. Surgical basis for arterial infusion chemotherapy of disseminated carcinoma of the liver. Surg Gynecol Obstet 120:581–605.Google Scholar
  25. 25.
    Cady B, Oberfield RA. 1974. Regional infusion chemotherapy of hepatic metastases from carcinoma of the colon. Am J Surg 127:220–227.PubMedCrossRefGoogle Scholar
  26. 26.
    Reed ML, Vaitkevicias VK, Al-Sarraf M et al. 1981. The practicality of chronic hepatic artery infusion therapy of primary and metastatic hepatic malignancies. Cancer 47:402–409.PubMedCrossRefGoogle Scholar
  27. 27.
    Ensminger W, Niederhuber J, Dakhil S et al. 1981. Totally implanted drug delivery system for hepatic artery chemotherapy. Cancer Treat Rep 65:393–400.PubMedGoogle Scholar
  28. 28.
    Niederhuben, JE, Ensminger W, Gyves J. 1984. Regional chemotherapy of colorectal cancer metastatic to liver Cancer 53:1336–1345.Google Scholar
  29. 29.
    Balch CM, Urest MM, Soong S et al. 1983. A prospective phase II clinical trial of continuous FUDR regional chemotherapy for colorectal metastases to the liver using a totally implantable drug infusion pump. Am Surg 198:567–573.CrossRefGoogle Scholar
  30. 30.
    Kemeny N, Daly JM, Oderman P et al. 1983. Hepatic infusion chemotherapy for metastatic colorectal carcinoma, results and complications. Proc ASCO 2:123 (C-482).Google Scholar
  31. 31.
    Kemeny N, Reichman B, Oderman J et al. 1986. Update of randomized study of intrahepatic (H) vs systemic (S) infusion of flurodeoxyuridine (FUDR) in patients with liver metastases from colorectal carcinoma (CRC). Proc Asco 5:89 (C-345).Google Scholar
  32. 32.
    Cohen Am, Kaufman SD, Wood WC et al. 1983. Regional hepatic chemotherapy using an implantable drug infusin pump. Am J Surg 145:529–533.PubMedCrossRefGoogle Scholar
  33. 33.
    Bertino JR, Lacy J et al. 1986. A phase I–II trial of intrahepatic (IH) sequential dichlorom-ethotrexate (DCM) and 5-fluorouracil (5-FU) chemotherapy for colon cancer metastatic to liver. Proc ASCO 5:94 (C-365).Google Scholar
  34. 34.
    Stagg RJ, Lewis BJ, Friedman MA, Ignoffo RJ, Hohn DC. 1984. Hepatic arterial chemotherapy for colorectal cancer metastatic to the liver. Review Ann Intern Med 100:736–743.CrossRefGoogle Scholar
  35. 35.
    Shapiro WR, Young DF, Mehta BM. 1975. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 293:101–166.Google Scholar
  36. 36.
    Blasberg R, Patlak C, Fenstermacher J et al. 1975. Intrathecal chemotherapy: Brain tissue profiles after ventriculo-cisternal perfusion. Perfusion J Pharmacol Exp Ther 195:73–83.Google Scholar
  37. 37.
    Dedrick RL, Myers CE, Bungay PM et al. 1978. Pharmacokinetic rational for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62:1–11.PubMedGoogle Scholar
  38. 38.
    Myers C, Collins J. 1983. Pharmacology of intraperitoneal chemotherapy. Cancer Invest 1:395–407.PubMedCrossRefGoogle Scholar
  39. 39.
    Howell S, Chu B, Wung W et al. 1981. Long duration intracavitary infusion of Methotrexate with systemic Leucovorin protection in patients with malignant effusions. J Clin Invest 67:1161–1170.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Myers C. 1984. The use of intraperitoneal chemotherapy in the treatment of ovarian cancer. Sem Oncol 11:275–284.Google Scholar
  41. 41.
    Collins JM. 1984. Pharmacologic rationale for regional drug delivery. J Clin Oncol 2:498–504.PubMedGoogle Scholar
  42. 42.
    Howell SB, Pfeifle CE, Wung WE, Olshen RA. 1983. Intraperitoneal Cis-diaminedichloro-platinum with systemic thiosulfate protection. Cancer Res 43:1476–1531.Google Scholar
  43. 43.
    Corden BJ, Hill JB, Collins J, Ozols RF. 1983. High dose Cis-Platinum in hypertonic saline absence of nephrotoxicity and pharmacokinetic of 40 mg/m2 × 5 schedule of administration. Proc ASCO 2:34 (C-132).Google Scholar
  44. 44.
    Ozols RF, Young RC, Speyer JL, Sugarbaker PH, Greene R, Jenkins J, Myers CE. 1982. Phase I and pharmacologic studies of Adriamycin intraperitoneally in patients with ovarian cancer. Cancer Res. 42:4265–4269.PubMedGoogle Scholar
  45. 45.
    Suhrland LG, Weisberger AS. 1965. Intracavitary 5-fluorouracil in malignant effusions. Arch. Intern. Med. 116:431–433.Google Scholar
  46. 46.
    Speyer JL, Sugarbaker PH, Collins JM et al. 1985. Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res 41:1916–1922.Google Scholar
  47. 47.
    Sugarbaker PH, Gianola FJ, Speyer JL et al. 1985. Prospective randomized trial of intravenous vs intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery 98:414–421.PubMedGoogle Scholar
  48. 48.
    Sigurdson ER, Ridge JA, Kemeny N, Daly JM. 1986. Comparison of drug uptake of colorectal hepatic metastases after hepatic artery and portal vein infusion. Proc ASCO 5:266 (C-1039).Google Scholar
  49. 49.
    Jones RB, Collins JM, Myers CC et al. 1981. High volume intraperitoneal chemotherapy with Methotrexate in patients with cancer. Cancer Res 41:55–59.PubMedGoogle Scholar
  50. 50.
    Alberts DS, Chen HSG, Chang SY, Peng YM. 1980. The disposition of intraperitoneal Bleomycin, Melphalan, and Vinblastine in cancer. Recent results. Cancer Res 74:293–299.Google Scholar
  51. 51.
    Mackman M, Cleary S, Lucas W, Howell S. 1985. Intraperitoneal chemotherapy with high dose Cis-Platinum and Cytosine Arabinoside for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity. J Clin Oncol 3:925–931.Google Scholar
  52. 52.
    Pfeifle CE, Howell SB, Markman M et al. 1984. Totally implantable system for peritoneal access. J Clin Oncol 2:1277–1280.PubMedGoogle Scholar
  53. 53.
    Dunnick N, Jones R, Doppman J et al. 1979. Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics. AJR 133:221–223.PubMedCrossRefGoogle Scholar
  54. 54.
    Gyves J, Ensminger W, Stetson P et al. 1984. Constant intraperitoneal 5-fluorouracil infusion through a totally imlanted system. Clin Pharmacol Ther 35:83–89.PubMedCrossRefGoogle Scholar
  55. 55.
    Myers C. 1985. The use of intraperitoneal chemotherapy. In: Important Advances in Oncology (Devita V, Hellman S, Rosenberg S, eds). Lippincott Co, Philadelphia, pp 218–225.Google Scholar
  56. 56.
    Bleyer WA, Poplack DG. 1985. Prophylaxis and treatment of leukemia in the central nervous system and other sactuaries. Oncol 12:131–148 (June).Google Scholar
  57. 57.
    Paladine W et al. 1976. Intracavitary bleomycin in the management of malignant effusions. Cancer 38:1903–1908.PubMedCrossRefGoogle Scholar
  58. 58.
    Theologides A. 1978. Neoplastic cardiac tamponade. Sem Oncol 5:181–192.Google Scholar
  59. 59.
    Stablein Donald. 1985. Statistical aspects of intraperitoneal chemotherapy studies. Sem Oncol XII, 3:121–123 (Sept).Google Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1986

Authors and Affiliations

  • Charles F. White
  • Karen Antman

There are no affiliations available

Personalised recommendations